Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935603 | 0.91 | FPR2 (1.00) | FPR2 | |
| SCHEMBL14948672 | 0.91 | FPR2 (0.85) | FPR2 | |
| SCHEMBL14935435 | 0.90 | FPR2 (0.83) | FPR2 | |
| SCHEMBL14935467 | 0.90 | FPR2 (0.84) | FPR2 | |
| SCHEMBL14935440 | 0.89 | FPR2 (1.00) | FPR2 | |
| SCHEMBL14935623 | 0.88 | FPR2 (1.00) | FPR2 | |
| SCHEMBL30198308 | 0.88 | FPR2 (1.00) | FPR2 | |
| SCHEMBL18306759 | 0.88 | FPR2 (1.00) | FPR2 | |
| SCHEMBL14935315 | 0.88 | FPR2 (0.81) | FPR2 | |
| SCHEMBL14935575 | 0.87 | FPR2 (1.00) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110279684-B | Use of formyl peptide receptor 2 agonists for the treatment of ocular inflammatory diseases | 阿勒根公司 | 2023-02-28 | — | — | CN | claimed |
| US-10899780-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | ALLERGAN, INC. (US) | 2021-01-26 | — | — | US | claimed |
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-14 | — | — | US | claimed |
| US-20190153004-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. | 2019-05-23 | — | — | US | claimed |
| EP-3103797-B1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-04-10 | — | — | EP | claimed |
| EP-3103797-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-12-14 | — | — | EP | claimed |
| EP-2776403-B1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-09-14 | — | — | EP | claimed |
| EP-2964213-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2016-01-13 | — | — | EP | claimed |
| EP-2964214-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2016-01-13 | — | — | EP | claimed |
| EP-2776403-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2014138037-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | claimed |
| WO-2014138046-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | claimed |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | claimed |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | claimed |
| US-8492556-B2 | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2013-07-23 | — | — | US | claimed |
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | claimed |
| WO-2013071203-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| EP-3795148-B1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN INC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885 |
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR2, FPR3 | FPR2 2/4885 |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885 |
| US-20190153004-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885 |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885 |
| US-10899780-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | FPR2, FPR1, FPR3 | FPR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.